Efficacy of XXXX , @entity3045 , and their combination in asthmatic @entity1 on high-dose inhaled steroids.

@entity1 @entity2544 @entity565 @entity3045 @entity288
A group of 32 @entity1 with moderately severe, chronic @entity565 (mean FEV1 55% of predicted), maintained on moderately high doses of inhaled @entity288 (mean dose 1,100 micrograms/d), participated in this double-blind, placebo-controlled crossover study. The effect on pulmonary function of adding @entity2544 (U, once daily @entity2544 ), inhaled @entity3045 (S, 200 micrograms four times per day), and their combination (C) or placebo (P) was assessed on Day 14 of each treatment phase. @entity1 recorded peak expiratory flow, @entity565 symptom severity (morning and evening), and use of rescue @entity3045 inhaler in daily diaries. Mean FEV1 between 0730 and 1800 h and maximum FEV1 between 0730 and 1300 h were significantly higher on U, S, and C compared with P (p < 0.006). Morning peak flow and FEV1 (0730 h) were significantly higher on U and C compared with S and P (p < 0.01). Evening peak flow was higher on U than P (p < 0.001), and C was higher than S and P (p < 0.01). Rescue @entity3045 inhaler use was significantly higher on P than on U, C, or S (p = 0.0001). @entity1 rating of @entity565 symptoms during C was significantly better than on S or P (p < 0.05). @entity1 rating of @entity565 control and study phase preference was significantly higher on combination and @entity2544 alone than on placebo, the combination also being superior to @entity3045 alone. Addition of @entity2544 or a combination of @entity2544 and @entity3045 significantly improves pulmonary function and @entity565 symptoms in @entity1 treated with high doses of inhaled @entity288 and as-needed beta agonists.(ABSTRACT TRUNCATED AT 250 WORDS)
